Neurometabolic Diseases Lab

  • Increase font size
  • Default font size
  • Decrease font size
Home Lines of Research Publications
Title Filter     Display # 
# Article Title Hits
41 Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet. 2012 Dec 1;21(23):5091-105. 842
42 ATP and noradrenaline activate CREB in astrocytes via noncanonical Ca(2+) and cyclic AMP independent pathways. Glia. 2012 Sep;60(9):1330-44. 685
43 The absence of ABCD2 sensitizes mice to disruptions in lipid metabolism by dietary erucic acid. J Lipid Res. 2012 Jun;53(6):1071-9 620
44 Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis (2012) 35:1137–1145. 624
45 Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta. 2012 Sep;1822(9):1475-88. 727
46 JNK/ERK/FAK mediate promigratory actions of basic fibroblast growth factor in astrocytes via CCL2 and COX2. Neurosignals. 2012;20(2):86-102. 639
47 Amyloid Generation and Dysfunctional Immunoproteasome Activation with Disease Progression in Animal Model of Familial Alzheimer's Disease. Brain Pathol. 2012 Sep;22(5):636-653. 616
48 Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. 2012 Mar 1;21(5):1062-77. 980
49 Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. 2012 Jun;46(3):508-26. 531
50 Antioxidants Halt Axonal Degeneration in a Mouse Model of X-Adrenoleukodystrophy. ANN NEUROL 2011;70:84–92 863
51 Phylogenomic evidence for a myxococcal contribution to the mitochondrial fatty acid beta-oxidation.PLoS One. 2011;6(7):e21989. 726
52 Oxidative Damage Compromises Energy Metabolism in the Axonal Degeneration Mouse Model of X-Adrenoleukodystrophy. Antioxid Redox Signal. 2011 Oct 15;15(8):2095-107 1145
53 Invariant NKT cells in adrenoleukodystrophy patients and mice.J Neuroimmunol. 2010 Dec 15;229(1-2):204-11. 925
54 Staging anti-inflammatory therapy in Alzheimer's disease. Front Aging Neurosci. 2010 Oct 25;2:142. 887
55 Current and Future Pharmacological Treatment Strategies in X-Linked Adrenoleukodystrophy. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):845-56. 1264
56 Pathomechanisms Underlying X-Adrenoleukodystrophy: A Three-Hit Hypothesis. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):838-44. 982
57 General Aspects and Neuropathology of X-Linked Adrenoleukodystrophy. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):817-30. 1252
58 Schilder's disease a heterogenous group of disorders known as X-linked adrenoleukodystrophy. Foreword.. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):815-6. 970
59 Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet. 2010 May 15;19(10):2005-14. Epub 2010 Feb 23. 1146
60 PeroxisomeDB 2.0: an integrative view of the global peroxisomal metabolome. Nucleic Acids Res. 2010 Jan;38(Database issue):D800-5. 1954
Page 3 of 4

View My Stats